Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase

Genmab A/S (NASDAQ:GMABGet Rating) shares saw an uptick in trading volume on Wednesday . 14,444 shares traded hands during trading, a decline of 98% from the previous session’s volume of 747,533 shares.The stock last traded at $30.08 and had previously closed at $30.40.

A number of research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Genmab A/S in a research report on Thursday, March 17th. Cowen started coverage on shares of Genmab A/S in a research report on Monday, May 2nd. They set a “market perform” rating for the company. SVB Leerink dropped their target price on shares of Genmab A/S from $42.00 to $39.00 and set a “market perform” rating on the stock in a report on Thursday, February 17th. Zacks Investment Research lowered shares of Genmab A/S from a “hold” rating to a “sell” rating in a research note on Thursday, January 20th. Finally, Berenberg Bank upgraded Genmab A/S from a “sell” rating to a “hold” rating in a research note on Friday, May 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S presently has an average rating of “Hold” and an average price target of $425.38.

The firm has a market capitalization of $19.72 billion, a price-to-earnings ratio of 53.33, a P/E/G ratio of 1.37 and a beta of 0.98. The company’s 50 day moving average is $34.76 and its 200-day moving average is $36.31.

Genmab A/S (NASDAQ:GMABGet Rating) last announced its earnings results on Wednesday, February 16th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.13 by $0.04. The company had revenue of $402.74 million for the quarter, compared to analysts’ expectations of $387.16 million. Genmab A/S had a net margin of 26.34% and a return on equity of 10.90%. Research analysts forecast that Genmab A/S will post 0.84 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after purchasing an additional 86,571 shares during the period. Wellington Management Group LLP lifted its holdings in Genmab A/S by 5.8% in the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock valued at $120,618,000 after buying an additional 183,578 shares during the period. Stifel Financial Corp lifted its holdings in Genmab A/S by 1.1% in the fourth quarter. Stifel Financial Corp now owns 1,209,423 shares of the company’s stock valued at $47,844,000 after buying an additional 12,587 shares during the period. Renaissance Technologies LLC lifted its holdings in Genmab A/S by 1.3% in the first quarter. Renaissance Technologies LLC now owns 1,088,500 shares of the company’s stock valued at $39,382,000 after buying an additional 14,100 shares during the period. Finally, Hardman Johnston Global Advisors LLC lifted its holdings in Genmab A/S by 0.9% in the third quarter. Hardman Johnston Global Advisors LLC now owns 1,079,269 shares of the company’s stock valued at $47,164,000 after buying an additional 10,013 shares during the period. Hedge funds and other institutional investors own 5.92% of the company’s stock.

Genmab A/S Company Profile (NASDAQ:GMAB)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.